Johnson & Johnson JNJ

$259.36 +5.57 (2.19%)

Valuation

Market cap
611,608,000,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.00
Forward PE
22.99
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
7,664,200
Avg volume
6,832,706
Day's range
$256.42 – $260.77
Shares out
2,409,898,000
Stochastic %K
74%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

SellasgpsCurativeBAT11 Oct 20, 11:36 PM
$AZN $BMY $JNJ $PFE $SLS I wrote Extensively about the fact that Sellas Headquarters Lease wasn’t Renewed during early October window like per usual occurrence every past year. A review of SEC filings shows SELLAS has extended its 7 Times Square sublease in one-year increments, each signed approximately 12 months before expiration: - December 11, 2023: extended to September 30, 2025 - October 2-3, 2024: extended to September 30, 2026 (8-K filed October 4) - October 1, 2025: extended to September 30, 2027 (8-K filed October 3) Under this pattern, an extension to September 30, 2028 would have been expected on or about October 1, 2026. As of the close on Friday, October 2, 2026 No filing was made. So BO is a foregone conclusion. I wouldn’t be surprised if we get Data+ deal in the same PR! ✌️🙏❤️‍🩹
0 replies
HboFam Oct 20, 8:09 PM
$SLS $JNJ $PFE $AZN who is going to believe this lying skeeze the next time it says it sold all off its SLS
2 replies
SellasgpsCurativeBAT11 Oct 20, 7:56 PM
$SLS $JNJ $PFE $AZN $BMY Looks like Sellas is sold ! ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 20, 7:48 PM
$JNJ $MRNA $SLS Big Pharmaceuticals have paid over $10 Billion this year for phase 1, phase 2 companies. Sellas MC too low with 2 Late stage Platform assets that can generate over $30 Billion annually by 2030. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 20, 7:44 PM
$JNJ $MRNA $SLS Massive orders moving through ASK on Level 2. Over 2.5 million volume in last 35 minutes. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 20, 7:39 PM
$JNJ $MRNA $SLS Shorts got 20 minutes to close there positions or get liquidated while trying. Time just ran out. 🔥 ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 20, 7:34 PM
$SLS $MRNA $JNJ Some of the most explosive biotech rallies have been preceded by seemingly inexplicable declines on little or no material news. Sentiment collapses, weak hands exit, and patience disappears just before a major catalyst completely resets valuations. $SLS is approaching one of the most consequential moments in its Corporate history. Dr. Stergiou next chapter is selling $SLS to big pharmaceutical suitor and new beginnings. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 20, 7:23 PM
$JNJ $SLS $MRNA you don't take your first 600-square-foot booth at ASH for nothing. $SLS is on the ASH 2026 floor plan at Booth 138 20× 30 ft, 600 sq ft, six times a standard booth. SELLAS did not exhibit at ASH 2025. ✌️🙏❤️‍🩹
0 replies